4B0G
Complex of Aurora-A bound to an Imidazopyridine-based inhibitor
Summary for 4B0G
Entry DOI | 10.2210/pdb4b0g/pdb |
Related | 1MQ4 1MUO 1OL5 1OL6 1OL7 2BMC 2C6D 2C6E 2J4Z 2J50 2W1C 2W1D 2W1E 2W1F 2W1G 2WQE 2WTV 2WTW 2X6D 2X6E 2X81 2XNE 2XNG 2XRU |
Descriptor | AURORA KINASE A, 6-bromo-2-(1-methyl-1H-imidazol-5-yl)-7-{4-[(5-methyl-1,2-oxazol-3-yl)methyl]piperazin-1-yl}-1H-imidazo[4,5-b]pyridine, SULFATE ION, ... (4 entities in total) |
Functional Keywords | transferase, mitosis |
Biological source | HOMO SAPIENS (HUMAN) |
Cellular location | Cytoplasm, cytoskeleton, centrosome: O14965 |
Total number of polymer chains | 1 |
Total formula weight | 33662.24 |
Authors | Kosmopoulou, M.,Bayliss, R. (deposition date: 2012-07-02, release date: 2013-03-13, Last modification date: 2023-12-20) |
Primary citation | Bavetsias, V.,Crumpler, S.,Sun, C.,Avery, S.,Atrash, B.,Faisal, A.,Moore, A.S.,Kosmopoulou, M.,Brown, N.,Sheldrake, P.W.,Bush, K.,Henley, A.,Box, G.,Valenti, M.,De Haven Brandon, A.,Raynaud, F.I.,Workman, P.,Eccles, S.A.,Bayliss, R.,Linardopoulos, S.,Blagg, J. Optimization of Imidazo[4,5-B]Pyridine-Based Kinase Inhibitors: Identification of a Dual Flt3/Aurora Kinase Inhibitor as an Orally Bioavailable Preclinical Development Candidate for the Treatment of Acute Myeloid Leukemia. J.Med.Chem., 55:8721-, 2012 Cited by PubMed: 23043539DOI: 10.1021/JM300952S PDB entries with the same primary citation |
Experimental method | X-RAY DIFFRACTION (2.5 Å) |
Structure validation
Download full validation report